The 561 prostate cancer patients treated with IMRT at Memorial Sloan-Kettering Cancer Center were classified into prognostic risk groups.

• 有561名前列腺癌患者在Memorial Sloan-Kettering癌症中心接收IMRT治疗，并被分到了预测风险组。